Bionano Genomics (BNGO) Resumen de Acciones
Bionano Genomics, Inc. junto con sus filiales, ofrece soluciones de análisis genómico en América, Europa, Oriente Medio, África, China, Japón, Corea del Sur, Singapur, India y Australia. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 3/6 |
| Crecimiento futuro | 2/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 3/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
BNGO Community Fair Values
Create NarrativeSee what 33 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Bionano Genomics, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$1.15 |
| Máximo en las últimas 52 semanas | US$5.50 |
| Mínimo de 52 semanas | US$1.06 |
| Beta | 1.62 |
| Cambio en 1 mes | -1.71% |
| Variación en 3 meses | -1.71% |
| Cambio de 1 año | -65.05% |
| Variación en 3 años | -99.69% |
| Variación en 5 años | -99.90% |
| Variación desde la OPV | -99.90% |
Noticias y actualizaciones recientes
Actualización de narrativa • Jun 24
BNGO: Reproductive And Prenatal Genomic Advances Will Drive Future Upside
Analysts have trimmed their Bionano Genomics price target to $5.00 from $5.50, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. What’s in the News for Bionano Genomics Published data from 13 optical genome mapping (OGM) studies covering 730 samples in reproductive health and prenatal genetics, highlighting use across infertility, assisted reproduction, recurrent pregnancy loss, prenatal diagnosis, and spontaneous abortion, with OGM assessed alongside karyotyping, CNV sequencing, whole exome sequencing, and long read sequencing.
Actualización de narrativa • Jun 08
BNGO: Clinical Genomic Wins Will Drive Future Quality Control Breakthroughs
Analysts have maintained their price target for Bionano Genomics at $4.00, citing minor adjustments to the discount rate, revenue growth assumptions, profit margin outlook, and future P/E inputs that together support keeping the previous valuation level unchanged. What's in the News Researchers at The University of Texas MD Anderson Cancer Center and Johns Hopkins University School of Medicine published a Modern Pathology study reporting that Bionano's optical genome mapping, or OGM, detected genomic abnormalities in 97.8% of T cell acute lymphoblastic leukemia cases, compared with 55% using conventional cytogenetic analysis, and provided additional genomic insights beyond standard methods in about 70% of cases.
Actualización de narrativa • May 25
BNGO: Growing Clinical Use Cases Will Support Future Upside Potential
Analysts have nudged their price target on Bionano Genomics slightly higher to $6.00, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E, which modestly adjust their outlook on the stock. What's in the News The company issued revenue guidance for Q2 2026, targeting US$7.5 million to US$7.8 million in revenue.Recent updates
Actualización de narrativa • Jun 24
BNGO: Reproductive And Prenatal Genomic Advances Will Drive Future Upside
Analysts have trimmed their Bionano Genomics price target to $5.00 from $5.50, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. What’s in the News for Bionano Genomics Published data from 13 optical genome mapping (OGM) studies covering 730 samples in reproductive health and prenatal genetics, highlighting use across infertility, assisted reproduction, recurrent pregnancy loss, prenatal diagnosis, and spontaneous abortion, with OGM assessed alongside karyotyping, CNV sequencing, whole exome sequencing, and long read sequencing.Actualización de narrativa • Jun 08
BNGO: Clinical Genomic Wins Will Drive Future Quality Control Breakthroughs
Analysts have maintained their price target for Bionano Genomics at $4.00, citing minor adjustments to the discount rate, revenue growth assumptions, profit margin outlook, and future P/E inputs that together support keeping the previous valuation level unchanged. What's in the News Researchers at The University of Texas MD Anderson Cancer Center and Johns Hopkins University School of Medicine published a Modern Pathology study reporting that Bionano's optical genome mapping, or OGM, detected genomic abnormalities in 97.8% of T cell acute lymphoblastic leukemia cases, compared with 55% using conventional cytogenetic analysis, and provided additional genomic insights beyond standard methods in about 70% of cases.Actualización de narrativa • May 25
BNGO: Growing Clinical Use Cases Will Support Future Upside Potential
Analysts have nudged their price target on Bionano Genomics slightly higher to $6.00, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E, which modestly adjust their outlook on the stock. What's in the News The company issued revenue guidance for Q2 2026, targeting US$7.5 million to US$7.8 million in revenue.Actualización de narrativa • May 03
BNGO: Clinical Evidence For Genome Mapping Will Support Long-Term Upside
Analysts have maintained their $6.00 price target for Bionano Genomics, noting only minor adjustments to assumptions for discount rate, revenue growth, profit margin and future P/E that do not materially change their overall view on the stock. What's in the News Bionano Genomics reported that its auditor, BDO LLP, issued an unqualified opinion in the 2025 Form 10-K while expressing doubt about the company’s ability to continue as a going concern, highlighting funding and liquidity risk that equity holders should monitor closely (10-K filing).Actualización de narrativa • Apr 19
BNGO: Gene Editing QC And Hematology Evidence Will Drive Long-Term Upside
Analysts have reduced their price targets for Bionano Genomics, lowering updated fair value estimates to $6.00 from $8.00, alongside slightly lower revenue growth and profit margin assumptions and a marginally reduced future P/E outlook. What's in the News Bionano Genomics published a multicenter study in the American Journal of Hematology showing that optical genome mapping, or OGM, identified pathogenic or likely pathogenic abnormalities in multiple myeloma samples, including cases where traditional methods such as karyotyping, FISH, and NGS had limited success or returned no result (American Journal of Hematology).Actualización de narrativa • Apr 05
BNGO: Future Gene Editing Quality Control Breakthroughs Will Drive Upside Potential
Analysts have cut their price target on Bionano Genomics roughly in half, to around $4.00 from about $8.00, pointing to a higher discount rate, slightly softer revenue growth expectations near 26%, a modestly better profit margin near 16%, and a higher future P/E multiple closer to 8x as key drivers of the reset. What's in the News A multicenter study in the American Journal of Hematology reported that Bionano's optical genome mapping, or OGM, was concordant with traditional methods in multiple myeloma and identified pathogenic or likely pathogenic abnormalities in a large cohort of 211 samples, including cases where standard tests such as karyotyping and FISH did not yield results (American Journal of Hematology).Actualización de narrativa • Mar 22
BNGO: Gene Editing Safety Data Will Support Future Upside Potential
Analysts have adjusted their price target for Bionano Genomics slightly, reflecting updated assumptions around discount rate, profit margin, revenue growth and future P/E. Together, these factors point to a modest recalibration of their valuation outlook in dollar terms.Actualización de narrativa • Mar 07
BNGO: Gene Editing Safety Insights Will Support Long-Term Upside Potential
Analysts have lowered their price target on Bionano Genomics by $2.00 to $5.50, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. These changes collectively point to a more conservative outlook for the shares.Actualización de narrativa • Feb 20
BNGO: Gene Editing Study And Mapping Sensitivity Will Support Future Upside
Analysts have raised their price target for Bionano Genomics to $12.59 from $12.37, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that reflect a recalibrated risk and earnings profile. What's in the News Bionano Genomics highlighted a peer-reviewed study in Molecular Therapy: Methods & Clinical Development that used optical genome mapping, or OGM, to assess genomic alterations from multiple gene editing approaches, including transposons, lentiviral transduction, and CRISPR-Cas9 locus insertion (Key Developments).Actualización de narrativa • Feb 06
BNGO: Gene Editing QC Study Will Support Long-Term Upside
Analysts have trimmed their price targets for Bionano Genomics, citing slightly higher assumed discount rates and modest tweaks to long term revenue growth, profit margin and future P/E assumptions that leave their fair value estimate broadly unchanged at around $8.00. What's in the News Bionano Genomics highlighted a peer-reviewed study in Molecular Therapy: Methods & Clinical Development that used its optical genome mapping (OGM) technology to detect genomic alterations introduced by transposons, lentiviral transduction and CRISPR-Cas9 locus insertion in human iPSC lines, supporting OGM as a potential tool for genome integrity QC in gene editing workflows (Key Developments).Artículo de análisis • Jan 30
Market Cool On Bionano Genomics, Inc.'s (NASDAQ:BNGO) Revenues
With a price-to-sales (or "P/S") ratio of 0.5x Bionano Genomics, Inc. ( NASDAQ:BNGO ) may be sending very bullish...Actualización de narrativa • Jan 23
BNGO: Clinical Study And Genome Mapping Progress Will Support Future Upside
Analysts have adjusted their price target on Bionano Genomics slightly, reflecting modest tweaks to assumptions on discount rate, profit margin, and future P/E. These changes keep their fair value estimate broadly unchanged at about $7.50 per share.Actualización de narrativa • Jan 09
BNGO: Leukemia Study And 2025 Revenue Outlook Will Support Long-Term Upside
Analysts have slightly adjusted their price target for Bionano Genomics, citing modest tweaks in assumptions around discount rate, revenue growth, profit margin, and future P/E as the drivers of this update. What's in the News Bionano Genomics issued earnings guidance for the fourth quarter of 2025, with revenue projected in a range of US$7.5 million to US$7.9 million.Actualización de narrativa • Dec 23
BNGO: Study-Driven Revenue Outlook Will Support Stronger Long-Term Upside Potential
Analysts have lowered their fair value estimate for Bionano Genomics from 11.00 dollars to 8.00 dollars. This reflects a higher perceived risk and cost of capital, despite slightly stronger expectations for revenue growth, profitability, and future valuation multiples.Actualización de narrativa • Dec 09
BNGO: Clinical Study Momentum Will Drive Stronger Demand And Upside Through 2025
Analysts have modestly reiterated their outlook on Bionano Genomics, keeping the price target effectively unchanged as incremental tweaks to the discount rate, revenue growth, and margin assumptions suggest a steady, but not markedly altered, risk reward profile. What's in the News Bionano Genomics issued new revenue guidance for fourth quarter 2025, targeting $7.5 million to $7.9 million, while reiterating full year 2025 revenue expectations of $26.0 million to $30.0 million (company guidance filing).Actualización de narrativa • Nov 25
BNGO: Clinical Study Results Will Drive Increased Demand Through 2025
Analysts have lowered their price target for Bionano Genomics from $9.50 to $7.50 per share, citing updated forecasts for valuation and growth. What's in the News Bionano Genomics initiated earnings guidance for the fourth quarter of 2025, projecting revenue between $7.5 million and $7.9 million, and reiterated full-year 2025 revenue guidance of $26.0 million to $30.0 million (company guidance).Artículo de análisis • Sep 14
A Piece Of The Puzzle Missing From Bionano Genomics, Inc.'s (NASDAQ:BNGO) 28% Share Price Climb
Bionano Genomics, Inc. ( NASDAQ:BNGO ) shareholders would be excited to see that the share price has had a great month...Actualización de narrativa • Aug 15
VIA Software And Optical Genome Mapping Will Improve Laboratory Efficiency
With both the consensus price target and future P/E holding steady, no notable valuation shift is apparent for Bionano Genomics, keeping fair value unchanged at $9.00. What's in the News Peer-reviewed study demonstrated Bionano's optical genome mapping (OGM) detects novel oncogenic structural variants in infant/toddler T-cell acute lymphoblastic leukemia missed by conventional cytogenetics, identifying distinct prognostic subgroups.Artículo de análisis • Jul 30
Investors Continue Waiting On Sidelines For Bionano Genomics, Inc. (NASDAQ:BNGO)
Bionano Genomics, Inc.'s ( NASDAQ:BNGO ) price-to-sales (or "P/S") ratio of 0.4x might make it look like a strong buy...
Nueva narrativa • Apr 16
VIA Software And Optical Genome Mapping Will Improve Laboratory Efficiency
Enhancements in customer utilization and lab efficiency are projected to boost consumable sales and revenue growth.Artículo de análisis • Apr 05
Revenues Working Against Bionano Genomics, Inc.'s (NASDAQ:BNGO) Share Price Following 26% Dive
To the annoyance of some shareholders, Bionano Genomics, Inc. ( NASDAQ:BNGO ) shares are down a considerable 26% in the...Artículo de análisis • Feb 11
Slammed 62% Bionano Genomics, Inc. (NASDAQ:BNGO) Screens Well Here But There Might Be A Catch
Bionano Genomics, Inc. ( NASDAQ:BNGO ) shareholders that were waiting for something to happen have been dealt a blow...Artículo de análisis • Dec 17
Bionano Genomics, Inc. (NASDAQ:BNGO) Might Not Be As Mispriced As It Looks
Bionano Genomics, Inc.'s ( NASDAQ:BNGO ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a strong buy...Artículo de análisis • Aug 29
Many Still Looking Away From Bionano Genomics, Inc. (NASDAQ:BNGO)
Bionano Genomics, Inc.'s ( NASDAQ:BNGO ) price-to-sales (or "P/S") ratio of 1.1x might make it look like a strong buy...Rentabilidad de los accionistas
| BNGO | US Life Sciences | Mercado US | |
|---|---|---|---|
| 7D | -1.7% | 2.1% | 1.6% |
| 1Y | -65.0% | 16.5% | 18.6% |
Rentabilidad vs. Industria: Los resultados de BNGO fueron inferiores a los de la industria US Life Sciences, que obtuvo un rendimiento del 16.5% el año pasado.
Rentabilidad vs. Mercado: BNGO obtuvo unos resultados inferiores a los del mercado US, que fueron del 18.6% el año pasado.
Volatilidad de los precios
| BNGO volatility | |
|---|---|
| BNGO Average Weekly Movement | 5.8% |
| Life Sciences Industry Average Movement | 8.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: BNGO no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de BNGO ha disminuido de 11% a 6% en el último año.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2003 | 96 | Al Luderer | bionano.com |
Bionano Genomics, Inc. junto con sus filiales, ofrece soluciones de análisis genómico en América, Europa, Oriente Medio, África, China, Japón, Corea del Sur, Singapur, India y Australia. La empresa ofrece software de análisis genómico que permite a los laboratorios de genómica analizar e interpretar datos en una serie de plataformas para generar visualizaciones de datos informativos con el fin de agilizar y simplificar la elaboración de informes sobre variantes causales. También proporciona sistemas Saphyr y Stratys, que son soluciones de muestra a resultado para el análisis de variaciones estructurales mediante mapeo genómico óptico para el análisis genómico y la comprensión de la variación y la función genéticas; instrumentos Saphyr y Stratys, que son generadores de imágenes de molécula única; Saphyr Chip, un consumible que empaqueta las matrices de nanocanales para la linealización del ADN; Bionano Prep Kits y kits de etiquetado de ADN, que proporcionan los reactivos y protocolos para extraer y etiquetar ADN de peso molecular ultraalto; y sistema de purificación iónica, que aísla y purifica moléculas de ácido nucleico.
Resumen de fundamentos de Bionano Genomics, Inc.
| Estadísticas fundamentales de BNGO | |
|---|---|
| Capitalización bursátil | US$13.20m |
| Beneficios(TTM) | -US$31.60m |
| Ingresos (TTM) | US$28.74m |
0.5x
Ratio precio-ventas (PS)-0.4x
Ratio precio-beneficio (PE)¿Está BNGO sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de BNGO | |
|---|---|
| Ingresos | US$28.74m |
| Coste de los ingresos | US$15.24m |
| Beneficio bruto | US$13.50m |
| Otros gastos | US$45.10m |
| Beneficios | -US$31.60m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -2.75 |
| Margen bruto | 46.97% |
| Margen de beneficio neto | -109.95% |
| Ratio deuda/patrimonio | 27.1% |
¿Cómo se ha desempeñado BNGO a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/06 06:43 |
| Precio de las acciones al final del día | 2026/07/02 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Bionano Genomics, Inc. está cubierta por 5 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Yi Chen | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |
| Kevin DeGeeter | Oppenheimer & Co. Inc. |